Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease

Nicole Quah Qin Xian1 Department of Stroke Medicine, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UKView further author information

Ahmed Alnahrawy2 Department of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UKView further author information

Rashmi Akshikar2 Department of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UKView further author information

Vickie Lee2 Department of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UK;3 Department of Surgery & Cancer, General Surgery, Faculty of Medicine,Imperial College London, London, UKCorrespondence[email protected]

https://orcid.org/0000-0002-2963-5742 View further author information

Figures & data

Table 1 Demographics and Baseline Characteristics of Our Cohort of 20 Individuals

Download CSV Display Table

Figure 1 Duration of mycophenolate mofetil treatment for 20 patients.

Figure 2 Flowchart demonstrating the treatments received by individuals with moderate-severe TED and those with DON at baseline, 24 weeks, 52 weeks and 78 weeks.

Table 2 Ophthalmic Assessments for Individuals with Moderate-Severe TED and Sight-Threatening DON at Baseline, 24 Weeks, 52 Weeks, 78 Weeks

Download CSV Display Table

Table 3 Ophthalmic Responses for Individuals with Moderate-Severe TED and Individuals with Sight-Threatening DON at 24 Weeks, 52 Weeks, 78 Weeks vs Baseline

Download CSV Display Table

Table 4 Relapses in Those with Moderate-Severe TED and Sight-Threatening DON Occurring by 24 Weeks, 52 Weeks, 78 Weeks

Download CSV Display Table

Table 5 Side Effects During Mycophenolate Mofetil Treatment for Our Cohort

Download CSV Display Table

Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease

Table 1 Demographics and Baseline Characteristics of Our Cohort of 20 Individuals

Table 2 Ophthalmic Assessments for Individuals with Moderate-Severe TED and Sight-Threatening DON at Baseline, 24 Weeks, 52 Weeks, 78 Weeks

Table 3 Ophthalmic Responses for Individuals with Moderate-Severe TED and Individuals with Sight-Threatening DON at 24 Weeks, 52 Weeks, 78 Weeks vs Baseline

Table 4 Relapses in Those with Moderate-Severe TED and Sight-Threatening DON Occurring by 24 Weeks, 52 Weeks, 78 Weeks

Table 5 Side Effects During Mycophenolate Mofetil Treatment for Our Cohort

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease

Figures & data

Table 1 Demographics and Baseline Characteristics of Our Cohort of 20 Individuals

Table 2 Ophthalmic Assessments for Individuals with Moderate-Severe TED and Sight-Threatening DON at Baseline, 24 Weeks, 52 Weeks, 78 Weeks

Table 3 Ophthalmic Responses for Individuals with Moderate-Severe TED and Individuals with Sight-Threatening DON at 24 Weeks, 52 Weeks, 78 Weeks vs Baseline

Table 4 Relapses in Those with Moderate-Severe TED and Sight-Threatening DON Occurring by 24 Weeks, 52 Weeks, 78 Weeks

Table 5 Side Effects During Mycophenolate Mofetil Treatment for Our Cohort

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date